ASA Makes Recommendations to FDA for Opioid Conversion Labeling

In a letter to the FDA, the American Society of Anesthesiologists has addressed public health concerns associated with the use of equianalgesic opioid conversion tables and has recommended a staged approach for opioid conversion labeling.  

Advertisement

According to ASA, “opioid conversion must emphasize the goal of safety by specifying the potential for dose adjustments after calculation of the equianalgesic dose.”

Download the full letter on the ASA website.

More Articles on Anesthesia:

Study: Prescription Painkiller Overdose Deaths in Women Spike 400% in 10 Years
Dr. Walter Schuyler Joins Pain Specialists of Charleston

Sibley Medical Center to Open Pain Management Clinic, Adds Dr. J. Richard Waggoner

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Anesthesia

  • The Morgantown-based West Virginia University School of Nursing is increasing its Doctor of Nursing Practice Nurse Anesthetist program from 15…

Advertisement

Comments are closed.